Patents by Inventor Quan Karen Zhu

Quan Karen Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST PD-1 AND METHODS OF USE THEREOF
    Publication number: 20220275088
    Abstract: The present invention is directed to human monoclonal antibodies that bind to the cell-surface receptor, PD-1 (programmed death 1). The antibodies can be used to treat cancer and chronic viral infections.
    Type: Application
    Filed: June 15, 2020
    Publication date: September 1, 2022
    Inventors: Wayne A. Marasco, Matthew Chang, Quan Karen Zhu
  • COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING
    Publication number: 20220213206
    Abstract: The present invention provides compositions and methods for augmenting antibody mediate receptor signaling.
    Type: Application
    Filed: February 6, 2018
    Publication date: July 7, 2022
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220098314
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: May 10, 2021
    Publication date: March 31, 2022
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • CHIMERIC ANTIGEN RECEPTOR FACTORIES AND METHODS OF USE THEREOF
    Publication number: 20220047634
    Abstract: This invention is directed to chimeric antigen receptors and cells comprising the same, wherein the cells further secrete monoclonal antibodies locally at a tumor site.
    Type: Application
    Filed: January 12, 2019
    Publication date: February 17, 2022
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Yufei Wang, Matthew Chang
  • Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
    Patent number: 11046777
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 29, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • ENGINEERED CELLS, T CELL IMMUNE MODULATING ANTIBODIES AND METHODS FOR USING THE SAME
    Publication number: 20210163570
    Abstract: This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.
    Type: Application
    Filed: March 14, 2019
    Publication date: June 3, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Emily Kuiper
  • GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210101989
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Application
    Filed: July 24, 2017
    Publication date: April 8, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210070860
    Abstract: The present invention provides compositions and methods for augmenting antibody mediate receptor signaling.
    Type: Application
    Filed: March 21, 2019
    Publication date: March 11, 2021
    Inventors: Wayne A. Marasco, Quan Karen Zhu, Matthew R. Chang